Interim report from DIAGNODE-1 supports continued positive clinical course after 15 months
Diamyd Medical today announces that a fourth interim report from the researcher-initiated trial DIAGNODE-1 shows a positive clinical progression in terms of the body’s own capacity to produce insulin, as well as long-term blood sugar and insulin dose when half of the patients have been followed for 15 months.In a fourth interim report from the open label researcher-initiated clinical pilot trial DIAGNODE-1, where the diabetes vaccine Diamyd® is administered directly into the lymph node, results are presented for six out of a total of twelve patients that have been followed for 15 months.